by Whitney Palmer (Diagnostic Imaging)
18F-FET PET to contrast-enhanced MR can better determine which patients are responding well to immune checkpoint inhibitors or targeted therapies.
Adding amino acid based PET to contrast-enhanced MR can help better determine if a treatment protocol is effective against metastatic brain disease.
According to Diagnostic Imaging, “Although new treatments for brain metastases, such as immune checkpoint inhibitors (ICI) and targeted therapies (TT), are effective, assessing just how well they are working in an individual patient can be difficult. The results produced by contrast-enhanced MRI can be variable, said a team of German investigators.”
“Essentially, these new treatments have requirements of brain imaging which cannot be met by conventional MRI,” said Norbert Galldiks, M.D., a neurology professor, as well as a neurologist and neuro-oncologist at the University Hospital Cologne and Research Center in Juelich, Germany. “In our study, we tried to determine if adding 18F-FET PET could help to overcome some of these imaging challenges.”
To read more, visit Diagnostic Imaging
